# Huasky Medical Holding

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huasky-medical-holding

- Industry: Outsourcing
- Headquarters: Beijing, China
- Website: www.huasky-cro.com
- Total disclosed funding: $50M
- Latest round: Series C (Jul 23, 2021)
- Investors on record: 4

## About

Established in 2005 and based in Beijing, China, Huasky Medical Holding Ltd operates as a clinical CRO company that provides SMO, third-party audit, CRO, pharmacovigilance, drug registration and medical device services. The company is a subsidiary of Yangpu Star Pharmaceutical Co.,Ltd. Xinmin Dai, the founder and chairman of the company, is vice chairman of the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce. Cailian Kang, the CEO and CMO of the company, graduated from Tongji Medical University and is the former CDE senior reviewer. In July 2021, it raised USD 50 million in series C funding from OrbiMed Advisors and SPDB International, and Springs Capital, Zhongyuan Capital, Xiading Capital, and Xinling Capital. In February 2023, Anshun City Government became the strategic partner of the company.

The company's business is divided into six series, which include SMO, third-party audit, CRO, pharmacovigilance, drug registration and medical device. It has many clients, such as Sinopharm, Sailing and Tennor Therapeutics.

## Funding rounds

- Series C, Jul 23, 2021, $50M — OrbiMed Advisors, Springs Capital, Zhongyuan Capital, SPDB International Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Springs Capital — Series C
- Zhongyuan Capital — Series C
- SPDB International Capital (https://capitalatlas.ai/funds/spdb-international-capital) — Series C